GLOPERBA

Peak

colchicine

NDAORALSOLUTION
Approved
Jan 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
14

Mechanism of Action

Colchicine's effectiveness as a prophylactic treatment for gout has been postulated to be due to its ability to block neutrophil mediated inflammatory responses induced by monosodium urate crystals in synovial fluid. Colchicine disrupts the polymerization of β-tubulin into microtubules, thereby…

Pharmacologic Class:

Alkaloid

Clinical Trials (5)

NCT06666335Phase 4Not Yet Recruiting

A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF

Started Sep 2025
3 enrolled
Familial Mediterranean Fever (FMF )
NCT06543082Phase 4Recruiting

MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

Started Aug 2024
490 enrolled
Acute Coronary Syndrome
NCT04516941Phase 3Terminated

CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19

Started Jan 2021
60 enrolled
SARS-CoV InfectionCOVID-19
NCT04139655N/AWithdrawn

Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study

Started Sep 2020
0
Myocardial InfarctionMyocardial InjuryMajor Adverse Cardiac Events+1 more
NCT01709981Phase 4Completed

Anti-inflammatory Effects of Colchicine in PCI

Started May 2013
280 enrolled
Coronary Artery Disease

Loss of Exclusivity

LOE Date
Dec 20, 2037
143 months away
Patent Expiry
Dec 20, 2037

Patent Records (5)

Patent #ExpiryTypeUse Code
10383820
Nov 22, 2036
Product
U-2814
10383821
Nov 22, 2036
Product
12274751
Nov 22, 2036
U-2814
12514819
Nov 22, 2036
U-2814
9907751
Nov 22, 2036
Product